The IL-2 - IL-2 Receptor Pathway: Key to Understanding Multiple Sclerosis

Overview

Journal J Transl Autoimmun

Date 2022 Jan 10

PMID 35005590

Authors

Daphne Peerlings

Max Mimpen

Jan Damoiseaux

Affiliations

Soon will be listed here.

Abstract

The development, progression, diagnosis and treatment of autoimmune diseases, such as multiple sclerosis (MS), are convoluted processes which remain incompletely understood. Multiple studies demonstrated that the interleukin (IL)-2 - IL-2 receptor (IL-2R) pathway plays a pivotal role within these processes. The most striking functions of the IL-2 - IL-2R pathway are the differential induction of autoimmune responses and tolerance. This paradoxical function of the IL-2 - IL-2R pathway may be an attractive therapeutic target for autoimmune diseases such as MS. However, the exact mechanisms that lead to autoimmunity or tolerance remain to be elucidated. Furthermore, another factor of this pathway, the soluble form of the IL-2R (sIL-2R), further complicates understanding the role of the IL-2 - IL-2R pathway in MS. The challenge is to unravel these mechanisms to prevent, diagnose and recover MS. In this review, first, the current knowledge of MS and the IL-2 - IL-2R pathway are summarized. Second, the key findings of the relation between the IL-2 - IL-2R pathway and MS have been highlighted. Eventually, this review may launch broad interest in the IL-2 - IL-2R pathway propelling further research in autoimmune diseases, including MS.

Citing Articles

Acetyl 11-Keto Beta-Boswellic Acid Improves Neurological Functions in a Mouse Model of Multiple Sclerosis.

Karima S, Khatami S, Ehtiati S, Khoshtinatnikkhouy S, Kachouei R, Jahan-Abad A Inflammation. 2024; .

PMID: 39487943 DOI: 10.1007/s10753-024-02176-2.

Simian varicella virus infection and reactivation in rhesus macaques trigger cytokine and Aβ40/42 alterations in serum and cerebrospinal fluid.

Niemeyer C, Traina-Dorge V, Doyle-Meyers L, Das A, Looper J, Mescher T J Neurovirol. 2024; 30(1):86-99.

PMID: 38453879 DOI: 10.1007/s13365-024-01196-w.

Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study.

Thorning M, Lambertsen K, Jensen H, Frich L, Madsen J, Olsen D Int J Mol Sci. 2024; 25(3).

PMID: 38338871 PMC: 10855557. DOI: 10.3390/ijms25031592.

Pain and the biochemistry of fibromyalgia: patterns of peripheral cytokines and chemokines contribute to the differentiation between fibromyalgia and controls and are associated with pain, fat infiltration and content.

Gerdle B, Dahlqvist Leinhard O, Lund E, Lundberg P, Forsgren M, Ghafouri B Front Pain Res (Lausanne). 2024; 5:1288024.

PMID: 38304854 PMC: 10830731. DOI: 10.3389/fpain.2024.1288024.

Induction of IL-2 by interleukin-12 p40 homodimer and IL-12, but not IL-23, in microglia and macrophages: Implications for multiple sclerosis.

Jana M, Mondal S, Jana A, Pahan K Cytokine. 2023; 174:156457.

PMID: 38056248 PMC: 10872483. DOI: 10.1016/j.cyto.2023.156457.

References

Buhelt S, Bach Sondergaard H, Oturai A, Ullum H, von Essen M, Sellebjerg F . Relationship between Multiple Sclerosis-Associated Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls. Cells. 2019; 8(6). PMC: 6628508. DOI: 10.3390/cells8060634. View

Martin J, Perry J, Jakhete N, Wang X, Bielekova B . An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol. 2010; 185(2):1311-20. PMC: 3085179. DOI: 10.4049/jimmunol.0902238. View

Arenas-Ramirez N, Woytschak J, Boyman O . Interleukin-2: Biology, Design and Application. Trends Immunol. 2015; 36(12):763-777. DOI: 10.1016/j.it.2015.10.003. View

Hartmann F, Khademi M, Aram J, Ammann S, Kockum I, Constantinescu C . Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nat Commun. 2014; 5:5056. DOI: 10.1038/ncomms6056. View

Kunkl M, Frascolla S, Amormino C, Volpe E, Tuosto L . T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis. Cells. 2020; 9(2). PMC: 7072830. DOI: 10.3390/cells9020482. View

Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M . Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017; 96(8):1241-1251. DOI: 10.1007/s00277-017-2993-y. View

Dendrou C, Plagnol V, Fung E, Yang J, Downes K, Cooper J . Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009; 41(9):1011-5. PMC: 2749506. DOI: 10.1038/ng.434. View

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

Freedman M, Muth K, Trotter J, Yoshizawa C, Antel J . Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis. Neurology. 1992; 42(8):1596-601. DOI: 10.1212/wnl.42.8.1596. View

10.

Wang X, Chen T . Meta-analysis of the association of IL2RA polymorphisms rs2104286 and rs12722489 with multiple sclerosis risk. Immunol Invest. 2018; 47(5):431-442. DOI: 10.1080/08820139.2018.1425699. View

11.

Sharief M, Thompson E . Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993; 56(2):169-74. PMC: 1014817. DOI: 10.1136/jnnp.56.2.169. View

12.

Hofman F, von Hanwehr R, Dinarello C, Mizel S, Hinton D, Merrill J . Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol. 1986; 136(9):3239-45. View

13.

Abbas A, Trotta E, Simeonov D, Marson A, Bluestone J . Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018; 3(25). DOI: 10.1126/sciimmunol.aat1482. View

14.

Russell S, Moore A, Fallon P, Walsh P . Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice. PLoS One. 2012; 7(10):e47748. PMC: 3471880. DOI: 10.1371/journal.pone.0047748. View

15.

Lucas R, Ponsonby A, Dear K, Valery P, Pender M, Taylor B . Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011; 76(6):540-8. DOI: 10.1212/WNL.0b013e31820af93d. View

16.

Damoiseaux J . The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin Immunol. 2020; 218:108515. DOI: 10.1016/j.clim.2020.108515. View

17.

Baarnhielm M, Hedstrom A, Kockum I, Sundqvist E, Gustafsson S, Hillert J . Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur J Neurol. 2012; 19(7):955-62. DOI: 10.1111/j.1468-1331.2011.03650.x. View

18.

Trotter J, Collins K, van der Veen R . Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. J Neuroimmunol. 1991; 33(1):29-36. DOI: 10.1016/0165-5728(91)90031-2. View

19.

van den Broek H, Damoiseaux J, De Baets M, Hupperts R . The influence of sex hormones on cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: a review. Mult Scler. 2005; 11(3):349-59. DOI: 10.1191/1352458505ms1174rr. View

20.

Kobayashi H, Tagaya Y, Han E, Kim I, Le N, Paik C . Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2. Cytokine. 2000; 11(12):1065-75. DOI: 10.1006/cyto.1999.0509. View